SEMINAR: 'How to generate research funding by leveraging your IP'

Dr Samantha South is a Life Sciences technology transfer manager in the Research Development & Innovation (RDI) office at UWA. She has a PhD in behavioural pharmacology and an extensive background in medical research which includes working at Cornell University (NY), The University of Queensland and The Garvan Institute (UNSW). She has previously been involved in managing honours and PhD students, writing journal articles and involved with journal review panels and the scientific advisory committee of the Australian Pain Society. She was the preclinical manager at TetraQ, a preclinical contract organization specializing in providing preclinical drug development services to the pharmaceutical, biotechnology and complementary medicine industries. This included contract research efficacy and pharmacokinetics assessment, development and validation of animal models of disease, managing an animal facility and participating on animal ethics committees. As such, she has extensive experience with commercial preclinical drug development strategies, regulatory milestones, and performance criteria (commercial go/no-go).

Samantha has an MBA and many years' experience in the technology transfer/biotech sector which includes the assessment and valuation of new technologies, devising IP protection strategies, managing out-licensing/partnering activities, raising investment into managing new start-up companies, research and licensing deals with a wide range of clients including Universities, SMEs, multinationals, state and federal governments. She is also currently involved on NHMRC development grant review panels and is the UWA nominee Director on new UWA spin-out companies, MiReven (miR-7 therapy) and Eridan (nanoparticle delivery).